Percutaneous Transluminal Coronary Angioplasty
13
3
3
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
23.1%
3 terminated out of 13 trials
57.1%
-29.4% vs benchmark
23%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions
XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Effect of Non-pharmacological Anti-anxiety Exercises on Perceived Stress and Cortisol Level Before Elective Per Cutaneous Transluminal Coronary Angioplasty
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
The SHINE-CTO Trial
Establish a Telecare Model of Acute Coronary Syndrome Patient With Heart Stent Implantation by a Non-invasive Wearable Device and Artificial Intelligence Cloud to Reducing Medical Adverse Events.
Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
The European Bifurcation Club Left Main Study
Persantin Preceding Elective PCI